Top EPS Revision Gainers: WBX Surges 43.5%, BBIO +21.1% on Competitor Setback
Today's top performers were led by Wallbox (WBX) surging 43.5% from a detected EPS revision on June 30. BridgeBio (BBIO) gained 21.1% on a competitor trial failure and a $1B equity raise. Robinhood (HOOD) rose 14.8% despite market headwinds, while Coincheck (CNCK) and iQIYI (IQ) posted double-digit gains driven by upward EPS revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| WBX | Technology | 2026-06-30 | +10.6pp | +43.5% |
| BBIO | Healthcare | 2026-06-30 | N/A | +21.1% |
| HOOD | Financial | 2026-06-30 | N/A | +14.8% |
| CNCK | Financial | 2026-06-30 | +1.4pp | +14.4% |
| IQ | Communication Services | 2026-07-05 | +2.5pp | +12.9% |
Why did WBX stock jump in July 2026?
WBX surged 43.5% (from $3.82 to $5.48) after analysts raised its forward EPS growth estimate from 50.6% to 61.3% on June 30.
The revision was reinforced by a $11.8 million equity raise and an additional $4 million investment announced on July 2. Wallbox also set July 7 as the date for its Q2 2026 earnings release, keeping investor attention on its turnaround. The stock’s 10.6 percentage-point revision in EPS growth triggered the screener and was quickly confirmed by strong price action.
WBX EPS revision history → · Screener snapshot from 2026-06-30 →
FAQ: WBX
Why did WBX stock jump in June 2026?
WBX jumped 43.5% after analysts raised its forward EPS growth estimate from 50.6% to 61.3% on June 30, followed by a $15.8 million capital infusion and an upcoming earnings catalyst.
Is WBX a buy after the rally?
The rally reflects a significant EPS revision and improved balance sheet, but investors should monitor the Q2 earnings report for confirmation of fundamentals.
What is WBX's EPS growth estimate?
Wallbox's forward EPS growth estimate was revised upward from 50.6% to 61.3% on June 30, a 10.6 percentage-point increase.
Why did BBIO stock jump in July 2026?
BBIO jumped 21.1% (from $74.48 to $90.17) after analysts raised its forward EPS growth estimate to 124.9% on June 30.
The move accelerated on July 9 when competitor AstraZeneca and Ionis reported a failed ATTR-CM trial, removing a major threat to BridgeBio’s Attruby franchise. A $1 billion preferred equity raise led by Sixth Street on July 1 also strengthened its balance sheet for upcoming launches. The combination of EPS revision, competitive tailwind, and capital raise drove the double-digit gain.
BBIO EPS revision history → · Screener snapshot from 2026-06-30 →
FAQ: BBIO
Why did BBIO stock jump in July 2026?
BBIO rose 21.1% after an EPS growth revision to 124.9%, then surged further on July 9 when a competitor’s ATTR-CM drug trial failed, boosting the outlook for BridgeBio’s Attruby.
Is BBIO a buy after the rally?
The EPS revision and competitor setback provide strong catalysts, but the $1B equity raise dilutes existing shares; the conversion price at ~$138 offers upside if the company delivers on launches.
What caused BBIO's surge?
The surge was driven by an upward EPS revision on June 30, a $1 billion capital injection on July 1, and a competitor trial failure on July 9 that strengthened BridgeBio’s market position.
Why did HOOD stock jump in July 2026?
HOOD rose 14.8% (from $100.28 to $115.11) after analysts raised its forward EPS growth estimate to 38.6% on June 30.
Despite a market sell-off on July 8 and the launch of zero-commission trading by rival Gemini on July 7, Robinhood shares held gains as analysts defended its retail relationship as a durable moat. The screener detected the EPS revision early, and the stock’s subsequent price action confirmed the upgrade. Crypto-industry analysts like Bitwise’s Matt Hougan called Robinhood a 'generational company,' supporting sentiment.
HOOD EPS revision history → · Screener snapshot from 2026-06-30 →
FAQ: HOOD
Why did HOOD stock jump in June 2026?
HOOD gained 14.8% after analysts raised its forward EPS growth estimate to 38.6% on June 30, with the rally persisting through market headwinds.
Is HOOD a buy after the rally?
The EPS revision and analyst bullishness signal confidence, but competition from Gemini and crypto-native platforms like Hyperliquid introduce risk; watch for revenue diversification.
What is HOOD's EPS growth estimate?
Robinhood's forward EPS growth estimate was revised to 38.6% on June 30, reflecting improved profitability expectations.
Why did CNCK stock jump in July 2026?
CNCK gained 14.4% (from $2.22 to $2.54) after analysts raised its forward EPS growth estimate from 135.0% to 136.4% on June 30.
No company-specific news emerged in the following days, suggesting the move was driven entirely by the EPS revision and broader crypto-related sector momentum. The 1.4 percentage-point revision, though small, was enough to trigger the screener and attract buying interest. The stock’s strong relative performance highlights the market’s focus on profitability improvements in the crypto/fintech space.
CNCK EPS revision history → · Screener snapshot from 2026-06-30 →
FAQ: CNCK
Why did CNCK stock jump in late June 2026?
CNCK rose 14.4% after analysts raised its forward EPS growth estimate from 135.0% to 136.4% on June 30, with no other news catalysts.
What is CNCK's EPS growth estimate?
Coincheck's forward EPS growth estimate was revised upward from 135.0% to 136.4% on June 30.
What caused CNCK's surge?
The surge was caused entirely by an upward EPS revision and positive sentiment in crypto/financial stocks, as no company-specific news was released.
Why did IQ stock jump in July 2026?
IQ rose 12.9% (from $1.01 to $1.14) after analysts raised its forward EPS growth estimate from 1230.4% to 1232.9% on July 5.
The revision reflects improving profitability expectations for the Chinese streaming platform, even as no material news surfaced. The move likely benefited from a broader rebound in Chinese ADRs and value stocks. The screener captured the early signal, and the price action confirmed the upgrade.
IQ EPS revision history → · Screener snapshot from 2026-07-05 →
FAQ: IQ
Why did IQ stock jump in July 2026?
IQ gained 12.9% after analysts raised its forward EPS growth estimate from 1230.4% to 1232.9% on July 5, supported by sector momentum in Chinese ADRs.
What is IQ's EPS growth estimate?
iQIYI's forward EPS growth estimate was revised upward from 1230.4% to 1232.9% on July 5.
Is IQ a buy after the rally?
The EPS revision suggests strong earnings momentum, but the low absolute price and lack of news warrant caution; the rally is largely technical and revision-driven.
Today's winners highlight strong momentum in EV charging (WBX), biotech (BBIO), and fintech (HOOD), with upward EPS revisions acting as a key catalyst across sectors.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →